These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30522045)

  • 1. Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer.
    Choi KH; Jeon JY; Lee YE; Kim SW; Kim SY; Yun YJ; Park KC
    Transl Oncol; 2019 Feb; 12(2):381-388. PubMed ID: 30522045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo.
    Kim SY; Kim SM; Chang H; Chang HS; Park CS; Lee YS
    Head Neck; 2020 Dec; 42(12):3678-3684. PubMed ID: 32896015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Anticancer Activity of
    Yun HJ; Kim HJ; Kim J; Kim SY; Chang HS; Park CS; Chang HJ; Park KC
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin combined with sorafenib synergistically inhibit the invasive ability through targeting metastasis-associated protein 2 expression in human renal cancer cells.
    Lee CC; Huang PY; Hsieh YH; Chen YS; Tsai JP
    Tzu Chi Med J; 2022; 34(2):192-199. PubMed ID: 35465276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer.
    Park KC; Kim SM; Jeon JY; Kim BW; Kim HK; Chang HJ; Lee YS; Kim SY; Choi SH; Park CS; Chang HS
    Neoplasia; 2017 Mar; 19(3):145-153. PubMed ID: 28142087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways.
    Wang L; Wu H; Wang Y; Xu S; Yang C; Zhang T; Liu Y; Wang F; Chen W; Li J; Sun L
    Heliyon; 2023 Aug; 9(8):e19154. PubMed ID: 37664741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Apoptotic Effects in MDA-MB-231 Triple-Negative Breast Cancer Cells Through a Synergistic Action of Luteolin and Paclitaxel.
    Tamanna S; Perumal E; Rajanathadurai J
    Cureus; 2024 Jul; 16(7):e65159. PubMed ID: 39176367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
    Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
    Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.
    Sumitomo M; Asano T; Asakuma J; Asano T; Horiguchi A; Hayakawa M
    Clin Cancer Res; 2004 Jan; 10(2):794-801. PubMed ID: 14760103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction.
    He B; Dai L; Zhang X; Chen D; Wu J; Feng X; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
    Int J Biol Sci; 2018; 14(13):1845-1858. PubMed ID: 30443188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells.
    Hsu FT; Chang B; Chiang IT; Wu TH; Hwang JJ
    In Vivo; 2014; 28(5):925-33. PubMed ID: 25189909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.
    Miyake M; Anai S; Fujimoto K; Ohnishi S; Kuwada M; Nakai Y; Inoue T; Tomioka A; Tanaka N; Hirao Y
    Oncol Lett; 2012 Jun; 3(6):1195-1202. PubMed ID: 22783417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
    Lin MT; Lin CL; Lin TY; Cheng CW; Yang SF; Lin CL; Wu CC; Hsieh YH; Tsai JP
    Tumour Biol; 2016 May; 37(5):6987-96. PubMed ID: 26662956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
    Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
    BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma.
    Kim C; Lee JH; Baek SH; Ko JH; Nam D; Ahn KS
    Phytother Res; 2017 Jul; 31(7):1078-1089. PubMed ID: 28544385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
    Shang D; Ito N; Kamoto T; Ogawa O
    Urology; 2007 May; 69(5):1007-12. PubMed ID: 17482960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.